Life Technologies Corporation

Thermo Fisher Scientific Baltics Uab

Biotechnologijos Institutas

Inga Cikotiene

Mark R Andersen

Sihong Chen

Arvydas Lubys

Daumantas Matulis

Michael D Allen

Zana Kapustina

Arturas Berezniakovas

Jurgita Matuliene

Simona Zeimyte

Justina Medziune

Egidijus Kazlauskas

The present disclosure describes oligonucleotide-tethered nucleotides, methods of making them, and methods of using them. The oligonucleotide-tethered nucleotides comprise, in some embodiments, a nucleotide linked to an oligonucleotide of from about 3 to about 100 nucleotides in length. These oligonucleotide-tethered nucleotides can be used to label a plurality of different types of nucleic acids in a plurality of different situations with a known oligonucleotide, which can serve as a barcode in some embodiments. The resulting oligonucleotide-labeled nucleic acids oligonucleotides can be used in a variety of nucleic acid sequencing methods.

Oligonucleotide-tethered nucleotides

Invention is related to novel compounds -5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles with general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit Hsp90 chaperone which participate in cancer progression. This invention is also related to new intermediate compounds which are used for the synthesis of thiadiazoles of general formula (I). 

5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone and the intermediates for production thereof

Growing community of inventors

Vilnius, Lithuania

Inga Cikotiene